<DOC>
	<DOCNO>NCT01204996</DOCNO>
	<brief_summary>The purpose study evaluate safety dose regimen CNTO 888 administer patient solid tumor combination 4 standard care chemotherapy regimen .</brief_summary>
	<brief_title>A Study Safety Efficacy CNTO 888 Combination With SoC ( Standard Care ) Chemotherapy Patients With Solid Tumors</brief_title>
	<detailed_description>CNTO 888 antibody work block protein call CC-chemokine ligand 2 ( CCL2 ) . In research study CCL2 , show increase growth new blood vessel help tumor survive . It hop block CCL2 may help control tumor growth . Patients receive one four treatment . A dose 15 mg/kg CNTO 888 administer every 3 week combination either docetaxel , gemcitabine , paclitaxel-carboplatin Treatment Arms 1 , 2 , 3 , respectively ; 10 mg/kg CNTO 888 administer every 2 week DOXIL® / Caelyx® ( doxorubicin HCl liposome injection ) intravenous infusion every 4 week Treatment Arm 4 . The maximum time patient study one year . Safety assessment conduct throughout course study . Safety assessment include monitoring side effect , clinical laboratory test ( hematology , biochemistry , urinalysis ) , vital sign , physical examination . CNTO 888 administer IV 2 different dos ( 15 mg/kg 10 mg/kg ) dependant chemotherapy combination . Combination therapy continue disease progression , unacceptable toxicity , patient refuse combination therapy , withdraws consent , treat 1 year</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Documentation advance solid tumor No 2 previous anticancer therapy good performance status adequate bone marrow , liver , renal function / adequate blood test value willing use birth control measure No residual toxicity result previous therapy know allergy , hypersensitivity , intolerance antibody chemotherapies clinically significant bleed require concurrent therapeutic dose anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>monoclonal antibody</keyword>
	<keyword>solid tumor</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>standard care</keyword>
</DOC>